Large Retrospective Evaluation of the Effectiveness and Safety of Ceftaroline Fosamil Therapy
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Ceftaroline has been approved for acute bacterial skin infections and community-acquired bacterial pneumonia. Limited clinical experience exists for use outside these indications. The objective of this study was to describe the outcomes of patients treated with ceftaroline for various infections. Retrospective analyses of patients receiving ceftaroline ≥72 h from 2011 to 2013 were included. Clinical and microbiological outcomes were analyzed. Clinical success was defined as resolution of all signs and symptoms of infection with no further need for escalation while on ceftaroline treatment during hospitalization. A total of 527 patients received ceftaroline, and 67% were treated for off-label indications. Twenty-eight percent (148/527) of patients had bacteremia. Most patients (80%) were initiated on ceftaroline after receipt of another antimicrobial, with 48% citing disease progression as a reason for switching. The median duration of ceftaroline treatment was 6 days, with an interquartile range of 4 to 9 days. A total of 327 (62%) patients were culture positive, and the most prevalent pathogen was Staphylococcus aureus , with a frequency of 83% (271/327). Of these patients, 88.9% (241/271) were infected with methicillin-resistant S. aureus (MRSA). Clinically, 88% (426/484) achieved clinical success and hospital mortality was seen in 8% (40/527). While on ceftaroline, adverse events were experienced in 8% (41/527) of the patients and 9% (28/307) were readmitted within 30 days after discharge for the same infection. Patients treated with ceftaroline for both FDA-approved and off-label infections had favorable outcomes. Further research is necessary to further describe the role of ceftaroline in a variety of infections and its impact on patient outcomes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2008.08.010 · Cited by 51,384
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
APACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376
APACHE II: a severity of disease classification system.
Knaus, W. A., Draper, E. S., Wagner, D. P., & Zimmerman, J. E. (1985) · PubMed · Cited by 6,034
Clinical and Laboratory Standards Institute
(2019) · Springer Reference Medizin · doi:10.1007/978-3-662-48986-4_300416 · Cited by 5,091
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Self-citationProposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis
Li, J. S., Sexton, D. J., Mick, N., Nettles, R., Fowler, V. G., Ryan, T., Bashore, T., & Corey, G. R. (2000) · Clinical Infectious Diseases · doi:10.1086/313753 · Cited by 4,027
Infectious Diseases Society of America
Enders, J. F. (1969) · Journal of Infectious Diseases · doi:10.1093/infdis/119.3.317 · Cited by 3,286
Lew, D. P., & Waldvogel, F. A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16727-5 · Cited by 1,883
Lipsky, B. A., Berendt, A. R., Cornia, P. B., Pile, J. C., Peters, E. J. G., Armstrong, D. G., Deery, H. G., Embil, J. M., Joseph, W. S., Karchmer, A. W., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis346 · Cited by 1,766
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459
van Hal, S. J., Paterson, D. L., & Lodise, T. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01568-12 · Cited by 639
van Hal, S. J., Lodise, T. P., & Paterson, D. L. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir935 · Cited by 512
The 10 × ‘20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020
(2010) · Clinical Infectious Diseases · doi:10.1086/652237 · Cited by 484
Wootton, M. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.4.399 · Cited by 414
Walsh, T. R., Bolmström, A., Qwärnström, A., Ho, P., Wootton, M., Howe, R. A., MacGowan, A. P., & Diekema, D. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.7.2439-2444.2001 · Cited by 319
Holmes, N. E., Turnidge, J. D., Munckhof, W. J., Robinson, J. O., Korman, T. M., O’Sullivan, M. V. N., Anderson, T. L., Roberts, S. A., Gao, W., Christiansen, K. J., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir270 · Cited by 228
Moore, C. L., Osaki-Kiyan, P., Haque, N. Z., Perri, M. B., Donabedian, S., & Zervos, M. J. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir764 · Cited by 220
Wilcox, M. H., Corey, G. R., Talbot, G. H., Thye, D., Friedland, D., Baculik, T., on behalf of the CANVAS 2 investigators, Manos, P., Lee, P., Bush, L., et al. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq255 · Cited by 216
File, T. M., Low, D. E., Eckburg, P. B., Talbot, G. H., Friedland, H. D., Lee, J., Llorens, L., Critchley, I. A., Thye, D. A., on behalf of the FOCUS 1 investigators, et al. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr096 · Cited by 197
Low, D. E., File, T. M., Eckburg, P. B., Talbot, G. H., David Friedland, H., Lee, J., Llorens, L., Critchley, I. A., Thye, D. A., on behalf of the FOCUS 2 investigators, et al. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr097 · Cited by 185
Murray, K. P., Zhao, J. J., Davis, S. L., Kullar, R., Kaye, K. S., Lephart, P., & Rybak, M. J. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit112 · Cited by 178
Self-citationCorey, G. R., Wilcox, M. H., Talbot, G. H., Thye, D., Friedland, D., Baculik, T., on behalf of the CANVAS 1 investigators, Mehra, P., Alpert, M., Baird, I., et al. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq254 · Cited by 165
van Hal, S. J., & Paterson, D. L. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01133-10 · Cited by 165
Kopp, B. J., Nix, D. E., & Armstrong, E. P. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1e028 · Cited by 148
Werth, B. J., Sakoulas, G., Rose, W. E., Pogliano, J., Tewhey, R., & Rybak, M. J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01586-12 · Cited by 134 · cited 1×
“This may have also accounted for some use of ceftaroline in our patient population (4–6), as ceftaroline has demonstrated in vitro activity against these resistant pathogens (29, 30).”
BackgroundSelf-citationHo, T. T., Cadena, J., Childs, L. M., Gonzalez-Velez, M., & Lewis, J. S. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks006 · Cited by 130
Zahar, J.-R., Clec'h, C., Tafflet, M., Garrouste-Orgeas, M., Jamali, S., Mourvillier, B., De Lassence, A., Descorps-Declere, A., Adrie, C., Beauregard, M.-A. C. D., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/496923 · Cited by 123
Rose, W. E., Schulz, L. T., Andes, D., Striker, R., Berti, A. D., Hutson, P. R., & Shukla, S. K. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00797-12 · Cited by 111
Lin, J. C., Fierer, J., Aung, G., Johns, S., Thomas, A., Jahng, M., Fierer, J., & Fierer, J. (2013) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-012-0449-9 · Cited by 109
Kelley, P. G., Gao, W., Ward, P. B., & Howden, B. P. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr066 · Cited by 99
Endocarditis Caused by Methicillin‐Resistant Staphylococcus aureus:Treatment Failure with Linezolid
Ruiz, M. E., Guerrero, I. C., & Tuazon, C. U. (2002) · Clinical Infectious Diseases · doi:10.1086/342698 · Cited by 98
Casapao, A. M., Leonard, S. N., Davis, S. L., Lodise, T. P., Patel, N., Goff, D. A., LaPlante, K. L., Potoski, B. A., & Rybak, M. J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00380-13 · Cited by 85
Self-citationKhatib, R., Jose, J., Musta, A., Sharma, M., Fakih, M. G., Johnson, L. B., Riederer, K., & Shemes, S. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr169 · Cited by 81
Vidaillac, C., Leonard, S. N., & Rybak, M. J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00636-09 · Cited by 70
Self-citationDavis, S. L., Scheetz, M. H., Bosso, J. A., Goff, D. A., & Rybak, M. J. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1327 · Cited by 61
Self-citationIn Vitro Activity of Ceftaroline against 623 Diverse Strains of Anaerobic Bacteria
Citron, D. M., Tyrrell, K. L., Merriam, C. V., & Goldstein, E. J. C. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01788-09 · Cited by 49
Joson, J., Grover, C. A., Downer, C., Pujar, T., & Heidari, A. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr234 · Cited by 31
Research works printed but not linked: 1
- Forest Laboratories, Inc. July 2013. Telfaro (ceftaroline fosamil). Package information. Forest Laboratories, Inc., St. Louis, MO.
Cited by
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Self-citationMethicillin-resistant Staphylococcus aureus: an overview of basic and clinical research
Turner, N. A., Sharma-Kuinkel, B. K., Maskarinec, S. A., Eichenberger, E. M., Shah, P. P., Carugati, M., Holland, T. L., & Fowler, V. G. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0147-4 · Cited by 2,051
Clinical Management of Staphylococcus aureus Bacteremia: A Review
Holland, T. L., Arnold, C., & Fowler, V. G. (2014) · JAMA · doi:10.1001/jama.2014.9743 · Cited by 449
Holland, T. L., Baddour, L. M., Bayer, A. S., Hoen, B., Miro, J. M., & Fowler, V. G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.59 · Cited by 406
Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
Choo, E. J., & Chambers, H. F. (2016) · Infection & Chemotherapy · doi:10.3947/ic.2016.48.4.267 · Cited by 168
Metadata
- Authors
- Casapao, A. M., Davis, S. L., Barr, V. O., Klinker, K. P., Goff, D. A., Barber, K. E., Kaye, K. S., Mynatt, R. P., Molloy, L. M., Pogue, J. M., & Rybak, M. J.
- Affiliations
- Eugene Applebaum College of Pharmacy and Health Sciences (US)
- Alexian Brothers Medical Center (US)
- UF Health Shands Hospital (US)
- The Ohio State University Wexner Medical Center (US)
- Wayne State University (US)
- Detroit Medical Center (US)
- ORCID
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2014-05
- Volume
- 58
- Issue
- 5
- Pages
- 2541-2546
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3993242
- OpenAlex
- W2161279982
- Semantic Scholar
- 958bc2cf85f61e5e776b3aa67cbfece16c5be761
- Cited by
- 108
- References
- 40
- Citations by year
- 2025: 1 · 2024: 6 · 2023: 7 · 2022: 6 · 2021: 9 · 2020: 6 · 2019: 13 · 2018: 5 · 2017: 11 · 2016: 16 · 2015: 17 · 2014: 11
- FWCI
- 12.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (T32AI0055402-06AI, R01AI054961, R21AI101381)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Keywords
- ceftaroline fosamil, off-label antibiotic use, acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, methicillin-resistant Staphylococcus aureus, bacteremia, clinical success, in-hospital mortality, adverse drug reactions, hospital readmission, Staphylococcus aureus infection
- MeSH terms
- Ceftaroline, Aged, Anti-Bacterial Agents, Cephalosporins, Female, Humans, Male, Middle Aged, Retrospective Studies, Skin Diseases, Bacterial, Community-Acquired Infections, Pneumonia, Bacterial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.